Trials / Completed
CompletedNCT01285466
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
A Phase Ib Multi-center, Open-label, 4-arm Dose-escalation Study of Oral BEZ235 and BKM120 in Combination With Weekly Paclitaxel in Patients With Advanced Solid Tumors and Weekly Paclitaxel/Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to determine the maximum tolerated dose (MTD) of BEZ235 and BKM120 in combination with weekly paclitaxel and weekly paclitaxel/trastuzumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BEZ235 + paclitaxel | |
| DRUG | BKM120 + paclitaxel | |
| DRUG | BEZ235 + paclitaxel + trastuzumab | |
| DRUG | BKM120 + paclitaxel + trastuzumab |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2011-01-28
- Last updated
- 2020-12-09
Locations
10 sites across 5 countries: Belgium, Germany, Netherlands, Spain, Switzerland
Source: ClinicalTrials.gov record NCT01285466. Inclusion in this directory is not an endorsement.